ASLAN PHARMACEUTICALS ADR REP 5 (NASDAQ:ASLN)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a note issued to investors on Friday. They currently have a $12.00 target price on the stock. HC Wainwright’s price objective would indicate a potential upside of 152.10% from the company’s current price.
The analysts wrote, “Our price target is derived from a market value of the firm at $382M. This valuation includes a discounted cash flow analysis based asset value of $392M for varlitinib and ASLAN003, using a 15% discount rate and 0.5% terminal growth rate and excluding $10M debt.””
Separately, Zacks Investment Research lowered ASLAN PHARMACEUTICALS ADR REP 5 from a “hold” rating to a “sell” rating in a research note on Thursday, September 20th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $10.94.
ASLAN PHARMACEUTICALS ADR REP 5 (NASDAQ:ASLN) last issued its quarterly earnings data on Thursday, November 8th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.27. Analysts predict that ASLAN PHARMACEUTICALS ADR REP 5 will post -1.41 earnings per share for the current fiscal year.
A number of hedge funds have recently modified their holdings of the stock. MYDA Advisors LLC purchased a new position in ASLAN PHARMACEUTICALS ADR REP 5 in the 2nd quarter worth $195,000. Platinum Investment Management Ltd. purchased a new position in ASLAN PHARMACEUTICALS ADR REP 5 in the 2nd quarter worth $2,532,000. Finally, Temasek Holdings Private Ltd purchased a new position in ASLAN PHARMACEUTICALS ADR REP 5 in the 2nd quarter worth $12,660,000. Institutional investors own 10.87% of the company’s stock.
About ASLAN PHARMACEUTICALS ADR REP 5
ASLAN Pharmaceuticals Limited, a clinical-stage oncology-focused biopharmaceutical company, engages in developing therapeutics for global markets. It targets diseases that are highly prevalent in Asia, and orphan indications in the United States and Europe. The company's product pipeline includes Varlitinib, a reversible small molecule pan-human epidermal growth factor receptor inhibitor that is being studied in global pivotal trials (TreeTopp) for biliary tract cancer, and conducting Phase 2/3 clinical trials for gastric cancer, as well as testing in a single-arm pivotal clinical trial in biliary tract cancer in China.
Read More: Hedge Funds – Risk or Reward?
Receive News & Ratings for ASLAN PHARMACEUTICALS ADR REP 5 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASLAN PHARMACEUTICALS ADR REP 5 and related companies with MarketBeat.com's FREE daily email newsletter.